Stuttgart
14.08.26 | 21:55
3,980 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,980 | 4,115 | 15.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | THX PHARMA: THX Pharma Reports Cash Position as of June 30, 2026 | 494 | Actusnews Wire | Lyon, France - July 9, 2026 - 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company focused on the treatment of rare neurological diseases, today announced its cash position... ► Artikel lesen | |
| THX PHARMA Aktie jetzt für 0€ handeln | |||||
| 23.06. | THX PHARMA: THX Pharma Announces the Appointment of Sophie Jacq Lapointe to its Board of Directors | 439 | Actusnews Wire | A recognized leader in the pharmaceutical and biotechnology industry joins the Board of Directors to support THX Pharma's next phase of growth and development.
Lyon, France - June 23, 2026 - 6:00... ► Artikel lesen | |
| 16.06. | THX PHARMA: Allinvest Securities Initiates Analyst Coverage on THX Pharma with Buy Recommendation | 553 | Actusnews Wire | Lyon, France - June 16, 2026 - 8:00 AM CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces the initiation... ► Artikel lesen | |
| 09.06. | Theranexus: THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day | 501 | ACCESS Newswire | The three partners are proud to jointly serve as Platinum Sponsors of the 2026 BDSRA Annual Family Conference, where they will provide an update on the Batten-1 program and the upcoming initiation of... ► Artikel lesen | |
| 09.06. | THERANEXUS: THX Pharma (Theranexus) and Exeltis secure EMA approval of the paediatric investigation plan (PIP) for TX01, unlocking the PUMA registration pathway | 769 | Actusnews Wire | Approval of the PIP by the EMA's Paediatric Committee (PDCO) clears a critical regulatory gate, paving the way for a Paediatric Use Marketing Authorisation (PUMA) submission and securing up to... ► Artikel lesen | |
| 09.06. | THERANEXUS: THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day | 1.577 | Actusnews Wire | The three partners are proud to jointly serve as Platinum Sponsors of the 2026 BDSRA Annual Family Conference, where they will provide an update on the Batten-1 program and the upcoming initiation... ► Artikel lesen | |
| 28.04. | THERANEXUS: THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update | 905 | Actusnews Wire | Lyon, France - April 28, 2026 - 7:00 p.m. CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces its... ► Artikel lesen | |
| 25.03. | THERANEXUS: THX Pharma Announces the Publication of its Letter to Shareholders | 596 | Actusnews Wire | Lyon, France - March 25, 2026, 6:30 pm CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of... ► Artikel lesen | |
| 19.02. | THERANEXUS: THX Pharma Reports Its Cash Position as of December 31, 2025 | 701 | Actusnews Wire | Lyon, France - February 19, 2026, 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces... ► Artikel lesen | |
| 17.02. | THX Pharma appoints Julien Veys as Deputy CEO | 8 | PMLiVE | ||
| 12.02. | THERANEXUS: THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex | 791 | Actusnews Wire | THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex
Lyon, France - February 12, 2026 - 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company... ► Artikel lesen | |
| 10.02. | THX Pharma and Biocodex Announce a Strategic Licensing Agreement in Batten, Gaucher and Niemann-Pick Type C Diseases | 550 | Business Wire | THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug candidates... ► Artikel lesen | |
| 10.02. | THERANEXUS: THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases | 937 | Actusnews Wire | Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including... ► Artikel lesen | |
| 20.01. | THERANEXUS: THX Pharma Announces its 2026 Financial Calendar | 584 | Actusnews Wire | Lyon, France - January 20, 2026, 18:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial... ► Artikel lesen | |
| 08.01. | THERANEXUS: THX Pharma announces the publication of its letter to shareholders | 644 | Actusnews Wire | Lyon, France - January 8, 2025, 6:00 PM CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of... ► Artikel lesen | |
| 07.01. | THERANEXUS: THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer | 626 | Actusnews Wire | Lyon, France - January 7, 2026, 8:00 a.m. CET - The Board of Directors of THX Pharma (Theranexus), a pharmaceutical company specializing in rare neurological diseases, today announces the appointment... ► Artikel lesen | |
| 13.11.25 | THERANEXUS: THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure | 881 | Actusnews Wire | Capital increase of €7.8 million through the issuance of 4,356,804 new shares at a unit price of €1.80
The transaction received strong support from existing shareholders, whose demand on irreducible... ► Artikel lesen | |
| 27.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.10.2025 | 730 | Xetra Newsboard | Das Instrument XPGB NO0010736879 VEND MARKETPLAC. B NK-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 27.10.2025 und ex Kapitalmassnahme am 28.10.2025 The instrument XPGB NO0010736879 VEND MARKETPLAC.... ► Artikel lesen | |
| 23.10.25 | THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million | 2.283 | Actusnews Wire | Subscription and guarantee commitments totaling €5.9 million, representing 75.5% of the envisaged capital increase
Subscription price: €1.80 per share, representing a 29.4% discount to the... ► Artikel lesen | |
| 14.10.25 | Thx Pharma And Exeltis Achieve Key Milestone Towards The Commercialization Of Tx01 | 793 | Actusnews Wire | THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
THX Pharma (Theranexus) and Exeltis have reached a pivotal milestone, setting the stage for the... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | 0,00 % | Drei Wege zum Krebsmedikament der Zukunft: BioNTech, Vidac Pharma und Pfizer im Onkologie-Check | Die Onkologie hat sich zum dynamischsten Innovationsfeld der Pharmabranche entwickelt. Dabei wird nicht nach einem Wundermittel gesucht, sondern man ist bestrebt, hochpräzise personalisierte Therapien... ► Artikel lesen | |
| EVOTEC | 3,446 | -2,87 % | Evotec Aktie: Lebenszeichen aus der Totenstille - wer kauft denn da? | Die auffällige Ruhe bei der Evotec Aktie, die im letzten 4investors.de-Chartcheck im Mittelpunkt stand, ist durchbrochen. Damals lautete die Frage, ob jemand leise in die Totenstille der Biotechnologie-Aktie... ► Artikel lesen | |
| BB BIOTECH | 56,30 | 0,00 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,005 | +4,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| MODERNA | 54,61 | -0,20 % | Moderna-Aktie: Plötzlich deutlich besser als BioNTech | Die Moderna-Aktie überrascht die Börse rund um das Wochenende mit einem neuen Höhenflug. Nachdem der Kurs des Biotech-Konzerns bereits am Freitag um +10% in die Höhe geschossen ist, setzt sich die gute... ► Artikel lesen | |
| VALNEVA | 3,061 | -0,33 % | Valneva: EMA startet Prüfung des Lyme-Borreliose-Impfstoffs | Pfizer und Valneva haben mit ihrem gemeinsam entwickelten Lyme-Borreliose-Impfstoffkandidaten PF-07307405 einen wichtigen regulatorischen Schritt in Europa erreicht. Die Europäische Arzneimittel-Agentur... ► Artikel lesen | |
| EPIGENOMICS | 0,910 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,950 | -0,14 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| STRYKER | 294,40 | +0,44 % | Stryker-Aktie: Startet über 352,65 US$ die nächste Rally? | Die Stryker-Aktie hat sich nach dem scharfen Rücksetzer aus dem Frühjahr deutlich erholt und notiert inzwischen wieder bei 345,81 US$. Damit rückt der entscheidende Widerstandsbereich um 352,65 US$... ► Artikel lesen | |
| BIOGEN | 180,96 | -0,19 % | Wolfe Research stuft Biogen und AbbVie hoch: Starke Pipeline und günstige Bewertung als Treiber | ||
| BIOFRONTERA | 2,350 | -2,08 % | Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation | ||
| ILLUMINA | 165,24 | +0,16 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 45,890 | -0,89 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| NANOREPRO | 1,925 | 0,00 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.08.2026 / 07:15... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 691,00 | -0,49 % | If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today |
Das Unternehmen THX PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THX PHARMA SA finden Sie auf Wallstreet Online.